

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name: Epilog * Website: www.epilog.world *

CEO name: Tal Shapsa Heiman * Cell phone number: 054-2476277 *

Select a CATEGORY: Health IT/Digital Health *

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

1. Longevity - How to Complete the Centenarian Decathlon?
2. Do we Know Enough About the Brain to Treat Neurological Disorders?
3. Are Cancer Therapeutics Fulfilling the Promise?
4. Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?
5. AI tapestry: optimizing the interaction of AI and Biopharma
6. Facts and Myths on Ex-Liver Delivery of Nucleic Acid Therapeutics
7. Patients are Consumers at Home – How Far Can They Manage Their Health?
8. Robots Dancing with Humans in the Healthcare Systems and Homes
9. Are Medical Devices Still Relevant in the Context of New Biology?
10. Let food be thy medicine and medicine be thy food
11. How do we make Academic Translation Medicine replicable and relevant?
12. Bio Convergence - Everything That Rises Must Converge.
13. Skin health and Beauty

You may delete the section instructions, leaving only the bolded bullet title

Answers below should not exceed 60 words per question:

Executive Summary / Investment Rational

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Epilog is developing the first of its kind companion tool for people dealing with life-limiting illness backed by the world's leading behavioral and palliative care experts. We provide early access to quality-of-life focused care, utilizing a holistic personalized approach and connecting people to health and non-health services in their community. We raised a pre-seed and currently in a live pilot with a global health insurance company, servicing more than 30 million members worldwide.

Core Technology

What is the technology, its uniqueness, and its value proposition?

Epilog's core technology supports a whole-person model of care, connecting clinical and behavioral data to support an end-to-end patient journey, starting with revealing

preferences and goals of care and all the way to facilitating access to goal-concordant care for patients with life-limiting illness. Our AI-powered companion identifies and responds to varying preferences and mental capacity over time, in real time.

Product Profile/Pipeline

Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Epilog established a design partnership with Discovery Health, a leading global health insurance group, which includes a pilot program with its members, started March. The pilot aims to demonstrate enhancing early access to palliative care and the end of life journey for Discovery Health members, whereby improving member satisfaction, improving the clinical outcomes for these patients and reducing total cost of care.

Business Strategy

Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Epilog's business model is B2B based on health plan efficiency gains in the first stage. Our patient-centric solution is aimed at improving member engagement and optimizing communication to the betterment of member experience and health services utilization.

What's Next?

R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Next, Epilog plans to begin similar pilot projects with our current pipeline of US based health plans, and in parallel pursue our clinical PoC with a leading university medical center, scheduled for H2 23 and 2024. To support these, as well as the transition to commercial development, Epilog plans to raise a seed round by the end of 2023.